Difference between revisions of "Classification of urothelial carcinoma by immunohistochemistry"
Jump to navigation
Jump to search
| Line 37: | Line 37: | ||
===Notes=== | ===Notes=== | ||
*A marker is considered POSITIVE when 20% of tumour cells are POSITIVE.<ref name=pmid34103388/> | |||
*GATA3 POSITIVE and CK5/6 POSITIVE cases are classified as ''luminal''.<ref name=pmid34103388/> | *GATA3 POSITIVE and CK5/6 POSITIVE cases are classified as ''luminal''.<ref name=pmid34103388/> | ||
*GATA3 NEGATIVE and CK5/6 NEGATIVE are ''unclassified''.<ref name=pmid34103388/> | *GATA3 NEGATIVE and CK5/6 NEGATIVE are ''unclassified''.<ref name=pmid34103388/> | ||
Revision as of 15:34, 12 January 2022
A classification of urothelial carcinoma by immunohistochemistry can be done with three immunostains.[1]
General
- A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.[2]
A simple classification of urothelial carcinoma by immunohistochemistry
| Urothelial carcinoma | |||||||||||||||||||||||||||||||||||||||||
| Luminal type GATA3 +ve (CK5/6 -ve) | Basal type CK5/6 +ve (GATA3 -ve) | ||||||||||||||||||||||||||||||||||||||||
| Genomically unstable p16 +ve | Urothelial-like p16 -ve | ||||||||||||||||||||||||||||||||||||||||
IHC
Panel:
- CK5/6.
- GATA3.
- p16.
Note:
- Twenty percent of the tumour cells is considered the cut-off for positive and negative.[1]
Sign out
The immunoprofile (GATA3 POSITIVE, p16 POSITIVE, CK5/6 negative,) is in keeping with UROTHELIAL CARCINOMA, LUMINAL TYPE, GENOMICALLY UNSTABLE.
The immunoprofile (GATA3 POSITIVE, p16 negative, CK5/6 negative) is in keeping with UROTHELIAL CARCINOMA, LUMINAL TYPE, UROTHELIAL-LIKE.
The immunoprofile (CK5/6 POSITIVE, GATA3 negative) is in keeping with UROTHELIAL CARCINOMA, BASAL TYPE.
Notes
- A marker is considered POSITIVE when 20% of tumour cells are POSITIVE.[1]
- GATA3 POSITIVE and CK5/6 POSITIVE cases are classified as luminal.[1]
- GATA3 NEGATIVE and CK5/6 NEGATIVE are unclassified.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR (June 2021). "Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression". J Clin Pathol. doi:10.1136/jclinpath-2021-207573. PMID 34103388.
- ↑ Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B (October 2016). "Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use". EBioMedicine 12: 105–117. doi:10.1016/j.ebiom.2016.08.036. PMC 5078592. PMID 27612592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078592/.